Naučne publikacije akademskog osoblja
Datum kreiranja: 16.10.2015.

Ivan Petković

Dodatne informacije

  • Lični podaci

  • Datum rođenja: 30.12.1976.
  • Mesto rođenja: Knjaževac, Srbija
  • Obrazovanje

  • Fakultet: Medicinski fakultet u Nišu
  • Odsek / Grupa / Smer: medicina
  • Godina diplomiranja: 2003.
  • Spisak publikacija

  • Knjige i udžbenici:

     


     

  • Radovi u časopisima sa IMPACT faktorom:

    1. Miljana Dzunic, Marija Andjelkovic-Apostolovic, Svetislav Vrbic, Ivica Pejcic, Ivan Petkovic, Ana Cvetanovic, Sasa Dinic. Survival of patients with liver metastases from colorectal cancer treated with bevacizumab and FOLFOX4. J BUON 2020; 25 (1): 212-9.  PMID: 32277634   IF (2019): 1.695 (M23) 5-IF 2020: awaiting


    2. Miljana Dzunic, Ivan Petkovic, Ana Cvetanovic, Svetislav Vrbic, Ivica Pejcic. Current and future targets and therapies in metastatic colorectal cancer - Status Change. J BUON 2019; 24 (5): 1785-92.  PMID: 31786838  IF 2019: 1.695 (M23) 5-IF 2019: 1.453


    3. Slavica Stojnev, Miljan Krstić, Jovana Čukuranović Kokoris, Irena Conić, Ivan Petković, Sonja Ilić, Jelena Milošević Stevanović, Ljubinka Janković Veličković. Prognostic impact of canonical TGF-β signaling in urothelial bladder cancer. Medicina (Kaunas) 2019;55 (6)302. doi:10.3390/medicina55060302  PMID: 31238579   IF (2019): 1.205       (M22)  5-IF 2019: 1.572


    4. Darko Antic, Jelena Jelicic, Goran Trajkovic, Milena Todorovic Balint, Jelena Bila, Olivera Markovic, Ivan Petkovic, Vesna Nikolic, Bosko Andjelic, Vladislava Djurasinovic, Aleksandra Sretenovic, Mihailo Smiljanic, Vojin Vukovic, Biljana Mihaljevic. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B-cell lymphoma?  The prognostic significance of comorbidities. Ann Hematol 2018; 97 (2): 267-76.  doi: 10.1007/s00277-017-3170-z  PMID: 29130134 IF 2018: 2.850   (M22) 5-IF 2018: 2.8


    5. Olivera Simonović, Milena Todorović, Biljana Mihaljević, Tatjana Stoimenov-Jevtović, Ivan Petković, Lana Mačukanović-Golubović, Goran Marjanović. Serum biomarkers and clinical characteristics of patients with classical Hodgkin lymphoma. Vojnosanit Pregl 2018; 75 (9): 911-917. doi: 10.2298/VSP160705018S     PMID: awaiting IF 2018: 0.272 (M23)  5-IF 2018: 0.4


    6. Slavica Stojnev, Miljan Krstić, Ivan Ilić, Ivan Petković, Simonida Stojanović, Predrag Cvetković, Pavle Randjelović, Ljubinka Veličković. Acute myocardial infarction with Trousseau’s syndrome: case report and review of the literature. W Indian Med J 2017; u štampi  doi:10.7727/wimj.2016.140 PMID: awaiting  IF 2016: 0.224  (M23) 5-IF 2016 0.3


    7. Ivan Petković, Ivica Pejčić, Danica Tiodorović, Miljan Krstić, Slavica Stojnev, Svetislav Vrbić. Transformation of primary cutaneous follicle centre lymphoma into primary cutaneous diffuse large B-cell lymphoma of other type. Postepy Dermatol Alergol 2017; 34 (6): 625-8.         doi:10.5114/pdia.2017.66625  PMID: 29422831 IF 2017: 1.471   (M23) 5-IF 2017: 1.407


    8. Biljana Mihaljevic, Jelena Jelicic, Boško Andjelic, Darko Antic, Olivera Markovic, Ivan PetkovicMaja Perunicic Jovanovic, Goran Trajkovic, Jelena Bila, Vladislava Djurasinovic, Aleksandra Sretenovic, Vojin Vukovic, Mihailo Smiljanic, Milena Todorovic Balint. FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma. Int J Hematol 2016; 104 (6): 692–9. doi: 10.1007/s12185–016–2099–7  PMID: 27714586 IF 2016: 1.610  (M23)  5-IF 2016: 1.621


    9. Ivan Petković, Slavica Stojnev, Miljan Krstić, Ivica Pejčić, Svetislav Vrbić. Synchronous mantle cell lymphoma and prostate adenocarcinoma-is it just a coincidence? Vojnosanit Pregl 2016; 73 (11): 1072-75. doi: 10.2298/VSP150425125P     PMID: 29341562  IF 2016: 0.367 (M23) 5-IF 2016: 0.3


    10. Ivan Petković. Current trends in the treatment of primary mediastinal large B-cell lymphoma-an overview. Contemp Oncol (Pozn) 2015; 19 (6): 428-35.  doi:10.5114/wo.2015.56388  PMID: 26843837  5-IF: 0.150 (M23) 


    11. Ivan Petkovic. Follicular lymphoma-reply. Turk J Hematol 2015; 32 (1): 95.  doi: 10.4274/tjh.2014.0380 PMID: 25805689  IF 2015: 0.827   (M26)  polemika u međunarodnom časopisu


    12. Ivan Petković, Ivica Pejčić, Svetislav Vrbić. Are we a step forward with targeted agents in resolving the enigma of mantle cell lymphoma? Contemp Oncol (Pozn) 2014; 18 (6): 377-83.    doi: 10.5114/wo.2014.45111 PMID: 25784834      5-IF: 0.150  (M23)


    13. Ivan Petković, Miljan Krstić, Ivica Pejcić, Svetislav Vrbić, Slavica Stojnev, Ana Cvetanović, Mirjana Balić, Mirjana Todorović. Renal infiltration of Follicular Lymphoma. Turk J Hematol 2014; 31 (3): 315-6.   doi: 10.4274/Tjh.2014.0013  PMID: 25330530  IF 2014: 0.360 (M23) 5-IF 2014: 0.3


    14. Ivica Pejcic, Ivan Petkovic, Svetislav  Vrbic, Sladjana Filipovic, Mirjana Balic, Ana Cvetanovic. Mantle cell lymphoma-current literature overview. J BUON 2014; 19 (2): 342-9.  PMID: 24965390  IF 2014: 0.761  (M23) 5-IF 2014: 0.6


    15.  Ana Cvetanovic, Svetislav Vrbic, Sladjana Filipovic, Ivica Pejcic, Dusan Milenkovic, Nikola Zivkovic, Milos Kostic, Ivan Petkovic. Clinical benefit of Cetuximab and prognostic values of Cetuximab-related skin toxicity in metastatic colorectal cancer: a single institution analysis. J BUON 2014; 19 (1): 83-90.    PMID: 24659647  IF 2014: 0.761  (M23) 5-IF 2014: 0.6


    16.  Ivica Pejcic, Svetislav Vrbic, Sladjana Filipovic, Mirjana Scekic, Ivan Petkovic, Ljiljana Pejcic. Concurrent chemoimmunotherapy: is it still the best option for the treatment of metastatic melanoma in patients with good performance status? J BUON 2010; 15 (3): 470-4.      PMID: 20954411         IF 2010: 0.482   (M23) 5-IF 2010: 0.6


    17.  Ivica Pejčić, Svetislav Vrbić, Slađana Filipović, Mirjana Šćekić, Ivan Petković, Ljiljana Pejčić, Nebojša Đenić. Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site. Vojnosanit Pregl 2010; 67 (9): 723-31.         doi:10.2298/VSP1009723P         PMID: 20954411    IF 2010: 0.199    (M23) 5-IF 2010: 0.2


     


     


     

  • Radovi u ostalim časopisima:

    1. Ivan PetkovićAleksandar Popović, Miljana Džunić, Ivica Pejčić. Nodal and extranodal peripheral T/NK-cell neoplasms: current aspects. Acta Fac Med Naiss 2020; 37 (2): 99-120.  doi: 10.5937/afmnai37-24708    (M51)


    2. Miljana Džunić, Bojana Pejčić, Marija Anđelković-Apostolović, Svetislav Vrbić, Ivica Pejčić, Ivan Petković. Predictors of therapy response and early reccurence in patients with potentially resectabile colorectal liver metastases treated with bevacizumab and FOLFOX4 as a conversion therapy. Acta Medica Medianae 2019; 58 (3): 72-9.      doi: 10.5633/amm.2019.0310  (M51) 


    3. Mladen Đorđević, Ivan Petković. Dichlor-acetate induced polyneuropathy in high grade follicular lymphoma patient. Acta Medica Medianae 2019;  58 (1): 102-5.  doi: 10.5633/amm.2019.0114    (M51)


    4. Ivica Pejčić, Ivan PetkovićAna Cvetanović, Irena Conić. Single center experience study with Pembrolizumab in patients with BRAF mutant negative metastatic melanoma. Acta Fac Med Naiss 2018; 35 (4): 267-72.  doi: 10.2478/afmnai-2018-0028    (M51)


    5. Slavica Stojnev, Ana Ristić, Miljan Krstić, Ana Ristić-Petrović, Irena Conić, Ivan Petković, Jelena Milenković, Ljubinka Janković-Veličković. Expression of epigenetic silencer EZH2 in early invasive pT1 urothelial bladder cancer. Acta Medica Medianae 2018; 57 (3): 48-54.  doi: 10.5633/amm.2018. 0306   (M51)


    6. Novica Dimić, Dragan Krasić, Bojana Stamenković, Marina Vlajković, Ivan Petković, Dragan Dimić, Miljan Krstić, Nikola Živković, Dušanka Marković. MALT lymphoma in primary Sjogren’s syndrome patient-a case report. Balneoclimatologia 2018; 42 (1): 229-39.  (M53)


    7. Jovan Nikolić, Aleksandra Milićević, Jadranka Paravina, Ivan Petković, Milica Mihailović, Miloš Stanković, Žaklina Mijović, Dragan Mihailović. Histopathologic and clinical features of rapidly progressive ALK-negative cutaneous anaplastic large T-cell lymphoma. Acta Medica Medianae 2017; 56 (3): 55-61.  doi: 10.5633/amm.2017.0309   (M51)


    8. Miodrag Vrbić, Ivan Petković, Svetislav Vrbić, Maja Jovanović, Aleksandar Ranković, Lidija  Popović-Dragonjić, Marina Djordjević-Spasić. Two-Year Complete Remission of Diffuse Large B-cell Lymphoma in an Immunological Nonresponder HIV -infected Patient: Case Report. Case Rep Oncol 2017; 10 (1): 356-360.     doi: 10.1159/0004718472  PMID: 28559819  (M51)


    9. Ivan Petković,  Ivica Pejčić, Svetislav Vrbić. Proteazomni inhibitori-racionala kliničke primene u tretmanu multiplog mijeloma. Racionalna Terapija 2016; 8 (2): 25-33.  doi: 10.5937/racter8-10447  (M52)


    10. Ivan Petković, Miljan Krstić, Slavica Stojnev, Ivica Pejčić, Svetislav Vrbić. Extensive bone marrow involvement in Hodgkin lymphoma patient. Acta Fac Med Naiss 2014; 31 (4): 261-5.                                    doi: 10.2478/afmnai-2014-0032   (M52)    


    11. Ivica Pejčić, Svetislav Vrbić, Mirjana Todorović, Ivan Petković, Mirjana Balić, Ana Stanković. Cancer of unknown primary site syndrome-CUP syndrome-diagnostic and therapeutic dillemas. Acta Fac Med Naiss 2014; 31 (2): 87-94.  doi: 10.2478/afmnai-2014-0010    (M52)


    12. Ivan Petković, Ivica Pejčić, Svetislav Vrbić. New frontiers of target therapy in oncology: acute promyelocytic leukemia. Acta Fac Med Naiss 2014; 31 (1): 17-28.   doi: 10.2478/afmnai-2014-0002  (M52) 


    13. Ivan Petković, Dragan Mihailović, Miljan Krstić, Ivica Pejčić, Svetislav Vrbić, Mirjana Balić. Burkitt lymphoma in elderly patients – a case report. Acta Fac Med Naiss 2013; 30 (2): 103-9.                        doi: 10.2478/v10283-012-0044-0   (M52)


    14. Ivan Petković, Dragan Mihailović, Miljan Krstić, Ivica Pejčić, Svetislav Vrbić, Mirjana Balić. Primary mantle cell lymphoma of gastrointestinal tract - a case report. Acta Medica Medianae 2012; 51 (3): 41-6.  doi: 10.5633/amm.2012.0307 (M52)

  • Radovi na naučnim skupovima međunarodnog značaja:

    1. Miljan Krstic, Maja Perunicic Jovanovic, Slavica Stojnev, Petar Jovanovic  Ivan Petkovic, Darko AnticClinicopathologic analysis of splenic lymphoma: three year experinece [Meeting Abstract]Abstract book pp 64, 134-5.  EAHP 19th Meeting of the European Association for Haematopathology, Edinburgh, Scotland, United Kingdom 2018  (M34)


    2. Jelena Jelicic, Darko Antic, Milena Todorovic Balint, Bosko Andjelic, Olivera Markovic,  Ivan Petkovic, Vesna Nikolic, Jelena Bila, Vladislava Djurasinovic, Aleksandra Sretenovic, Vojin Vukovic, Mihailo Smiljanic, Snezana Sretenovic, Biljana Mihaljevic. High comorbidity index along with high NCCN-IPI strongly influence survival of diffuse large B cell lymphoma patients: Serbian Lymphoma Group experience  [Meeting Abstract]. Haematologica 2017; 102 (Suppl 2): 399.   (M34) 


    3.  Jelena Jelicic, Darko Antic, Milena Todorovic Balint, Bosko Andjelic, Olivera Markovic,  Ivan PetkovicVesna Nikolic, Jelena Bila, Vladislava Djurasinovic, Aleksandra Sretenovic, Vojin Vukovic, Mihailo Smiljanic, Snezana Sretenovic, Biljana Mihaljevic. Low albumin level correlates with poorer survival of patients with diffuse large B cell lymphoma: Serbian Lymphoma Group experience [Meeting Abstract]. Haematologica 2017; 102 (Suppl 2): 688.   (M34) 


    4. Miljan Krstic, Slavica Stojnev, Ivan Petkovic. STAT3 expression in diffuse large B–cell lymphoma of nodal and extranodal localization [Meeting Abstract]. Abstract book pp 75, 145-6.  EAHP 18th Meeting of the European Association for Haematopathology, Basel, Switzerland 2016 (M34)


    5. Jelena Jelicic, Milena Todorovic, Bosko Andjelic, Darko Antic, Olivera Markovic,  Ivan Petkovic, Aleksandra Sretenovic, Jelena Bila, Vojin Vukovic, Vladislava Djurasinovic, Mihailo Smiljanic, Ivica Pejicic, Biljana Mihaljevic. The absolute lymphocyte count as independent pararmeter may predict prognosis of follicular lymphoma patients [Meeting Abstract]. Haematologica 2016; 101 (Suppl 1): 753.   (M34) 


    6. Jelena Jelicic, Milena Todorovic Balint, Darko Antic, Bosko Andjelic, Olivera Markovic, Ivan Petkovic, Aleksandra Sretenovic, Jelena Bila, Vojin Vukovic, Vladislava Djurasinovic, Mihailo Smiljanic, Ivica Pejicic, Biljana Mihaljevic. Analysis of clinical parameters, absolute lymphocyte count in patients with diffuse large B cell lymphoma [Meeting Abstract]. Haematologica 2016; 101 (Suppl 1): 706.  (M34)  


    7. Jelena Jelicic, Milena Todorovic, Darko Antic, Jelena Bila, Bosko Andjelic, Dejana Stanisavljevic, Vladislava Djurasinovic, Aleksandra Sretenovic, Vojin Vukovic, Mihajlo Smiljanic, Ivan PetkovicIvica Vrbic, Biljana Mihaljevic. The role of prognostic and comorbidity indexes in patients with diffuse large B cell lymphoma treated with immunochemotherapy [Meeting Abstract]. Haematologica 2015; 100 (Suppl 1): 660-1.  (M34) 


    8. Vesna Nikolić, Darko Antić, Boško Andjelić, Milena Todorović, Tomislav Vukićević, Ivica Pejčić, Ivan Petković, Stevan Popović, Lazar Popović, Nebojša Andjelković, Snežana Sretenović, Olivera Marković, Jelena Knežević, Biljana Mihaljević. Prognostički značaj Ki-67 indeksa u bolesnika sa difuznim krupnoćelijskim B-limfomom koji su lečeni Rituximabom plus CHOP-iskustva Srpske limfomske grupe [Meeting Abstract]. 2. Kongres hematologa Srbije/6th Balkan Day Haematology, Belgrade 2011. Abstract book pp 08, 23-5. (M34)


    9. Mihaljević Biljana, Antić Darko, Anđelić Boško, Todorović Milena, Vukićević Tomislav, Nikolić Vesna, Pejčić Ivica, Petković Ivan, Popović Lazar, Anđelković Nebojša, Sretenović Snežana, Smiljanić Mihailo, Marković Olivera. Prognostic significance of the Ki-67 index in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP-experience of Serbian Lymphoma Study Group [Meeting Abstract]. Haematologica 2011; 96 (Suppl 2): 575-6.  (M34)


    10. Mihaljević Biljana, Antić Darko, Anđelić Boško, Vukićević Tomislav, Nikolić Vesna, Pejčić Ivica, Petković Ivan, Popović Stevan, Popović Lazar, Anđelković Nebojša, Sretenović Snežana, Leković Danijela, Smiljanić Mihailo, Marković Olivera, Knežević V, Kecman Vladimir. Characteristics of 917 Non-Hodgkin Lymphoma Patients in Serbia According to the WHO Classification of Lymphoid Neoplasms-Lira National Register-Based Study [Meeting Abstract].  Ann Oncol 2011; 22 (4): 204.  (M34)


    11. Mihaljević Biljana, Anđelić Boško, Antić Darko, Todorović Milena, Vukićević Tomislav, Nikolić Vesna, Pejčić Ivica, Petković Ivan, Popović Stevan, Savić Ivanka, Popović Lazar, Anđelković Nebojša, Sretenović Snežana, Knežević Jelena, Kecman Vladimir. Diffuse Large B-cell Lymphoma: Germinal Center Vs Non Germinal Center - Treatment Response on Immunochemotherapy. Serbian Lymphoma Study Group [Meeting Abstract]. Ann Oncol 2011; 22 (4): 224-5.   (M34)


     


     

  • Radovi na domaćim naučnim skupovima:

    1. Miljana Džunić, Mirjana Stanić, Saša Dinić, Ivan Petković, Svetislav Vrbić, Miroslav Stojanović. Prognostički parametri kod pacijenata sa metastazama kolorektalnog karcinoma u jetri operisanih nakon konverzione biohemioterapije.   Abstract Book pp, 268-9.  Kancerološka nedelja, 56. Onkološki Kongres, Beograd 2019. (M64) 


    2. Ivan Petković, Emilija Vagaja, Aleksandar Popović, Miljan Krstić, Ivica Pejčić. DA–EPOCH–R bez radioterapije vs. R–CHOP21+radioterapija su bez signifikante razlike na ishod lečenja bolesnika sa primarnim medijastinalnim B krupnoćelijskim limfomom. Abstract book pp 008, 125. 4. Kongres hematologa Srbije, Niš 2019.  (M64)  


    3. Ivan Petković, Emilija Vagaja, Aleksandar Popović, Miljan Krstić, Ivica Pejčić. Rezidualna PET/CT pozitivnost ne korelira sa rezistencijom/ progresijom bolesti nakon DA–EPOCH–R indukcije kod primarnog medijastinalnog B krupnoćelijskog limfoma. Abstract book up 09, 100.  4. Kongres hematologa Srbije, Niš 2019.  (M64) usmeno izlaganje


    4. Tatjana Petković, Vesna Radojičić, Ivan Petković. Specifičnosti zdravstvene nege pacijenata sa metastatskim tumorima sa nepoznatim primarnim ishodištem.  Abstract Book op, 299-300. Kancerološka nedelja, 55. Onkološki Kongres, Beograd 2018.  (M64) 


    5. Ivan Petković, Ivica Pejčić, Svetislav Vrbić, Mirjana Balić.  Prediktivni značaj Muris skora kod bolesnika sa difuznim B krupnoćelijskim limfomom tretiranih imunohemioterapijom. Abstract book op 19, 242-3.  Treći Kongres hematologa Srbije, Kragujevac 2015.  (M62) usmeno izlaganje


    6. Ivan Petković, Ivica Pejčić, Svetislav Vrbić, Mirjana Balić. Značaj nivoa beta 2 mikroglobulina kod bolesnika sa difuznim krupnoćelijskim B limfomom u eri primene rituksimaba. Abstract book p 53, 312-3.  Treći Kongres hematologa Srbije, Kragujevac 2015.  (M64)


    7. Ivan Petković, Ivica Pejčić, Svetislav Vrbić, Mirjana Balić.  Muški pol je faktor rizika za smrtni ishod kod bolesnika sa difuznim B krupnoćelijskim limfomom. Abstract book p 52, 311-2. Treći Kongres hematologa Srbije, Kragujevac 2015.  (M64) 


    8. Ivan Petković. Uticaj starosti pacijenata na izbor tretmana kod novodijagnostikovanih difuznih B krupnoćelijskih limfoma. Abstract book pp 39, 218-22. Treći Kongres hematologa Srbije, Kragujevac 2015.  (M61) predavanje po pozivu


    9. Jelena Jeličić, Milena Todorović, Darko Antić, Jelena Bila, Boško Anđelić, Dragomir Stanisavljević, Vojin Vuković, Vladislava Đurašinović, Aleksandra Sretenović, Mihailo Smiljanić, Ivan Petković, Ivica Pejčić, Biljana Mihaljević. Prognostički značaj komorbiditeta kod bolesnika sa difuznim B krupnoćelijskim limfomom lečenih imunohemioterapijom. Abstract book op 21, 121. Treći Kongres hematologa Srbije, Kragujevac 2015.   (M64) 


    10. Miljan Krstić, Slavica Stojnev, Ivan Petković, Svetislav Vrbić, Ivica Pejčić. Ekspresija STAT3 u difuznom B-krupnoćelijskom limfomu nodalne i ekstranodalne lokalizacije. Abstract book p 55, 314-5. Treći Kongres hematologa Srbije, Kragujevac 2015.  (M64)


    11. Vrbić Svetislav, Pejčić Ivica, Simonović Nataša, Petković Ivan. Medikamentozna onkološka terapija medularnog tireoidnog karcinoma. Zbornik radova sa recenzijom, Medicinski fakultet Niš 2009: 86-90. (M63)


     

Poslednji put izmenjeno utorak, 28 jul 2020 16:52